Neurotechnology company Neuralink, founded by Elon Musk, plans to implement its chips for up to 20,000 people annually with the goal of increasing annual revenue to over one billion dollars by 2031. The company plans to open five major clinics and release three different versions of brain implants that will allow control of computers by thought, restore vision, and treat various diseases such as tremors and Parkinson's disease.
These plans involve opening five major clinics over six years and releasing three different versions of brain implants. Among them are Telepathy, which will allow control of computers by thought; Blindsight, designed to restore vision; and Deep, aimed at treating conditions such as tremors and Parkinson's disease.
Neuralink's future plans include obtaining regulatory approval for the Telepathy device by 2029 and performing up to 2,000 operations a year with revenue of 100 million dollars. The company also plans to launch the Blindsight technology by 2030 with 10,000 operations per year and revenue of over 500 million dollars.
Currently, ten patients who have already been implanted with Neuralink chips are known, and they are all in the clinical trial phase. These plans demonstrate the company's deep ambitions in the field of neurotechnology and medicine.
Elon Musk's Neuralink is developing ambitious future plans, including the implementation of chips in thousands of people to revolutionize the fields of neurotechnology and medicine.